The short-term effect of near infrared irradiation on arteriovenous fistula in hemodialysis patients: a pilot, prospective study.

Arteriovenous fistula (AVF) is the preferred vascular access for maintenance hemodialysis (MHD) patients. This is a pilot trial evaluates short-term near-infrared (NIR) therapy for AVF in MHD patients. Between July and September 2023, 60 MHD patients at Peking University Third Hospital were screened. Of these, 44 were enrolled and randomized, and 42 completed the study. The JLP-800 infrared therapy device (Input voltage 220 V, oscillation mode, wavelength 600–3400 nm, 0–21 W output, the output power is 70%, and the energy density is 31.8 J/cm2) was used to illuminate AVF for 30-min. The safety index was the skin temperature of the AVF. Hemodynamic alterations and regional biomarker profiles were assessed via intention-to-treat analysis with longitudinal pre-/post-NIR exposure comparisons. The results demonstrated the safety of NIR for AVFs. The Interleukin‑6 (IL‑6) on AVF and systemic level of NIR group decreased significantly compared to controls [ -0.46 pg/mL (IQR: -1.84 to 0.19) versus + 0.23 pg/mL (IQR: -0.23 to 0.79); -0.53 pg/mL (IQR: -2.05 to 0.07) versus + 0.86 pg/mL (IQR: -0.37 to 4.27)]. After 30-min, theinterleukin‑10 (IL‑10) on the AVF in the NIR group increased significantly. Compared with the control group, the rise in interleukin‑8 (IL‑8)on the AVF of NIR was more modest. The CD4+/CD8 + on the AVF and systemic increased significantly in NIR group [1.48(0.00,2.84) vs. 2.07(0.55,3.48), P < 0.05; 1.66(0.00, 2.71) vs. 1.94(0.60, 3.80), P < 0.05]. This pilot study suggests that short-term NIR irradiation of the AVF in hemodialysis patients appears to be safe and may potentially attenuate the inflammatory response to some extent.Clinical trial registration number: ChiCTR2300071305 (05/10/2023).